Literature DB >> 16086866

[Epidermal growth factor receptor mutation in Chinese patients with non-small cell lung cancer].

Zhen-Kui Pan1, Li Zhang, Xing Zhang, Xin Wang, Ning Li, Fei Xu, Jian-Hua Chang, Zhong-Zhen Guan.   

Abstract

BACKGROUND &
OBJECTIVE: Recent studies showed that somatic mutations in epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain are associated with sensitivity of non-small cell lung cancer(NSCLC) to TK inhibitor gefitinib. The mutations, including in-frame deletions at exon 19 and substitutions at exon 18 or exon 21, cluster around ATP-binding pocket of TK domain. The frequency of mutations are higher in Japanese patients than in American patients. This study was to analyze EGFR mutations in Chinese patients with NSCLC.
METHODS: From Jun. to Oct. 2004, fresh specimens of lung cancer and corresponding normal lung tissue were collected from 52 consecutive NSCLC patients (39 men and 13 women) treated in Cancer Center of Sun Yat-sen University. All patients had not received treatment of gefitinib. DNA was extracted from the 52 specimens. Exons 19 and 21 were amplified by polymerase chain reaction (PCR), and sequenced and analyzed from both sense and antisense directions.
RESULTS: Somatic mutations in TK domain of EGFR in tumors were identified from 10 of the 52 (19.2%) patients, including 7 cases of in-frame deletion in exon 19 and 3 cases of amino acid substitution in exon 21. Mutation rate was significantly higher in adenocarcinoma, adeno-squamous carcinoma, and bronchioloalveolar cancer than in squamous cell carcinoma [26.1% (6/23), 40.0% (2/5), and 50.0% (2/4) vs. 0 (0/20), P=0.025], and significantly higher in non-smokers than in smokers [41.8% (7/17) vs. 8.6% (3/35), P=0.009]. Mutation rate in women was similar to that in men [23.1% (3/13) vs. 18.0% (7/39), P=0.697].
CONCLUSION: EGFR mutation rate in Chinese NSCLC patients is similar to that in Japanese patients, and is obviously higher than that in Caucasian population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16086866

Source DB:  PubMed          Journal:  Ai Zheng


  6 in total

1.  Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.

Authors:  Bibhu Ranjan Das; Sangeet Bhaumik; Firoz Ahmad; Aziz Mandsaurwala; Heena Satam
Journal:  Pathol Oncol Res       Date:  2015-01-31       Impact factor: 3.201

Review 2.  Tumor control versus adverse events with targeted anticancer therapies.

Authors:  Dorothy M K Keefe; Emma H Bateman
Journal:  Nat Rev Clin Oncol       Date:  2011-12-20       Impact factor: 66.675

3.  [Detection of EGFR gene mutations in 100 non-small cell lung cancer clinical samples by a real-time polymerase chain reaction method using amplification refractory mutation system specific primers and Taqman fluorescence probes].

Authors:  Jing Zhao; Jinyin Zhao; Xiao Zhao; Weijun Chen; Wei Zhong; Li Zhang; Longyun Li; Mengzhao Wang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-01

4.  EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas.

Authors:  Yan Liu; Mei Lin Xu; Hao Hao Zhong; Wan Jie Heng; Bing Quan Wu
Journal:  Pathol Oncol Res       Date:  2008-11-05       Impact factor: 3.201

5.  Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.

Authors:  Ling Zhang; Yunxia Li; Shaohong Zhang; Chen Gao; Keke Nie; Youxin Ji
Journal:  Cancer Biol Med       Date:  2018-05       Impact factor: 4.248

6.  [Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma].

Authors:  Zhihui Zhang; Xilan Wu; Jianming Ying; Junling Li; Tian Qiu; Huiqin Guo; Huan Zhao; Ling Shan; Yun Ling
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.